ArticleWorld journal of clinical cases2020
Predictive value of serum cystatin C for risk of mortality in severe and critically ill patients with COVID-19.
Article in World journal of clinical cases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Prognostic Performance of Cystatin C in COVID-19: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta-regression.Advances in medical sciences · 2021Pooled it
- Warning indicators of COVID-19 severity: a retrospective observational study integrating modern biomarkers and traditional tongue features.Frontiers in medicine · 2025Article
- Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function.International journal of molecular sciences · 2024Review
- Serum Cystatin C Levels as a Predictor of Severity and Mortality Among Patients With COVID-19 Infection.Cureus · 2023Article
- Serum cystatin C and inflammatory factors related to COVID-19 consequences.BMC infectious diseases · 2023Article
- Development of a biomarker signature using grating-coupled fluorescence plasmonic microarray for diagnosis of MIS-C.Frontiers in bioengineering and biotechnology · 2023Article
- The role of kidney injury biomarkers in COVID-19.Renal failure · 2022Review
- Exploratory analysis of interleukin-38 in hospitalized COVID-19 patients.Immunity, inflammation and disease · 2022Article
- Differential Bias for Creatinine- and Cystatin C- Derived Estimated Glomerular Filtration Rate in Critical COVID-19.Biomedicines · 2022Article
- Role of cystatin C and calprotectin as potential early prognostic biomarkers in COVID-19 patients admitted to a dedicated COVID care facility.Journal of family medicine and primary care · 2022Article
- Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically-ill COVID-19 patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2022Article
- Renal and Inflammation Markers-Renalase, Cystatin C, and NGAL Levels in Asymptomatic and Symptomatic SARS-CoV-2 Infection in a One-Month Follow-Up Study.Diagnostics (Basel, Switzerland) · 2022Article
- Using different machine learning models to classify patients into mild and severe cases of COVID-19 based on multivariate blood testing.Journal of medical virology · 2022Article
- Divergence between serum creatine and cystatin C in estimating glomerular filtration rate of critically ill COVID-19 patients.Renal failure · 2021Article
- Cystatin C is a marker for acute kidney injury, but not for mortality among COVID-19 patients in Mexico.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. COVID-19 is clinically categorized into mild, moderate, severe, and critical illness. Acute kidney injury is an independent risk factor for poor prognosis in patients with. Serum cystatin C (sCys C) is considered a more sensitive biomarker for early renal insufficiency than conventional indicators of renal function. Early detection of risk factors that affect the prognosis of severe and critically ill patients while using active and effective treatment measures is very important and can effectively reduce the potential mortality rate.
aimTo determine the predictive value of sCys C for the prognosis of patients with COVID-19.
methodsThe clinical data of 101 severe and critically ill patients with COVID-19 at a designated hospital in Wuhan, Hubei Province, China were analyzed retrospectively. According to the clinical outcome, the patients were divided into a discharge group (64 cases) and a death group (37 cases). The general information, underlying diseases, and laboratory examination indexes of the two groups were compared. Multivariate Cox regression was used to explore the relationship between sCys C and prognosis. The receiver operating characteristic (ROC) curve was used to demonstrate the sensitivity and specificity of sCys C and its optimal cut-off value for predicting death.
resultsThere were significant differences in age, sCys C, creatinine, C-reactive protein, serum albumin, creatine kinase-MB, alkaline phosphatase, lactate dehydrogenase, neutrophil count, and lymphocyte count between the two groups (
conclusionsCys C is an independent risk factor for death in patients with COVID-19. Patients with a sCys C level of 0.80 mg/L or greater are at a high risk of death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.